Research at Aurigene Oncology Ltd. has led to the identification of fused bicyclic heterocyclyl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer.
Epidermal growth factor receptor (EGFR) is involved in cell proliferation leading to malignant transformation, and for that it is considered a therapeutic target for treatment and prevention in lung and other cancers.
Katholieke Universiteit Leuven and Springworks Therapeutics Inc. have jointly identified tetrahydropyridopyrimidines acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors.
A Retune Pharma Inc. patent describes new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of cancer, thyroid-associated ophthalmopathy (Graves ophthalmopathy) and autoimmune disease.
CCM Biosciences Inc. has launched with a focus on discovering and developing novel drugs, including small molecules, gene therapies, biologics and nanomedicines, and companion diagnostic tests.
Verismo Therapeutics Inc., the U.S. subsidiary of South Korea’s HLB Co. Ltd., inked a license agreement with the University of Pennsylvania for two newly discovered CD19 binders – one of which will be used to develop Synkir-310, its investigative CAR T therapy for blood cancers.
Verastem Oncology Inc. and Genfleet Therapeutics Ltd. have inked a discovery and development deal to advance three oncology discovery programs targeting RAS pathway-driven cancers.
RSS
